“This year, all our pre-filled syringe COVID-19 vaccine doses for Canada are on track to be produced entirely within the country, starting at our new mRNA manufacturing facility in Laval, Quebec, and completed at our fill-finish partner in Cambridge, Ontario,” Raos says.

“This end-to-end domestic supply chain enables fast delivery, greater self-reliance, and a more agile response to evolving public health threats.”